Brexit: listed derivatives face OTC mutation

No-deal would flip EU27 users into different regime for UK-listed trades

lme-entrance
LME warned customers that futures could be treated as OTC “from an EU law perspective”

Swaths of the UK’s listed derivatives would be redefined as over-the-counter instruments following a no-deal Brexit, hiking costs for European Union end-users and potentially tipping them into a compliance minefield.

OTC and listed derivatives are subject to different sets of rules, with some swaps requirements not translating easily to listed products. In addition, swaps clearing and margining mandates are applied in part by adding up the notional values of a firm’s OTC trades. Converting

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact [email protected] or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact [email protected] to find out more.

To continue reading...

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here: